Krystal Biotech (KRYS) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$440.5M

Revenue (quarter)

$119.2M

Revenue growth (year over year)

+24.14%

Gross profit (trailing twelve months)

$416.9M

Gross margin

94.64%

Net income (trailing twelve months)

$241.5M

Net income (quarter)

$54.8M

Net income growth (year over year)

+42.87%

Net margin

54.82%

Return on equity

20.12%

EPS (trailing twelve months)

$8.27

Book value per share

$45.92

P/E (trailing twelve months)

40.54

Price to book

7.20

Debt to assets

9.43%

Payout ratio

—

Dividend yield

—

Company profile

Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.

• Is Krystal Biotech (KRYS) profitable?

  Yes. Krystal Biotech earned $241.5M in net income over the trailing twelve months, a net margin of 54.82%.

• How much revenue does Krystal Biotech (KRYS) make?

  Krystal Biotech generated $440.5M in revenue over the trailing twelve months, up 24.14% year over year.

• What is KRYS's P/E ratio?

  Krystal Biotech trades at 40.5 times trailing twelve-month earnings, on an EPS of $8.27.

• How do I buy stock in Krystal Biotech (KRYS)?

  KRYS trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.